Follow-up blood cultures are often needed after bacteremia

Article Type
Changed
Fri, 02/01/2019 - 06:51
Display Headline
Follow-up blood cultures are often needed after bacteremia

Bacteremia is common and associated with significant morbidity and mortality. Bloodstream infections rank among the leading causes of death in North America and Europe.1

See related article

In this issue, Mushtaq et al2 contend that follow-up blood cultures after initial bacteremia are not needed for most hospitalized patients. Not repeating blood cultures after initial bacteremia has been proposed to decrease hospitalization length, consultations, and healthcare costs in some clinical settings. However, without follow-up cultures, it can be difficult to assess the adequacy of treatment of bacteremia and associated underlying infections.

GRAM-NEGATIVE ORGANISMS

Results of retrospective studies indicate that follow-up cultures may not be routinely needed for gram-negative bacteremia. In a review by Canzoneri et al of 383 cases with subsequent follow-up cultures,3 55 (14%) were positive. The mean duration of bacteremia was 2.8 days (range 1 to 15 days). Of the 55 persistently positive blood cultures, only 8 (15%) were caused by gram-negative organisms. Limitations to this study included the lack of patient outcome data, a low event rate, and the retrospective design.4

In a retrospective case-control study of follow-up cultures for 862 episodes of Klebsiella pneumoniae bacteremia,5 independent risk factors for persistent bacteremia were intra-abdominal infection, higher Charlson comorbidity index score, solid-organ transplant, and unfavorable treatment response.

These studies confirm that persistent bacteremia is uncommon with gram-negative organisms. They also support using comorbidities and treatment response to guide the ordering of follow-up blood cultures.

WHEN IS FOLLOW-UP CULTURE USEFUL?

Although follow-up blood cultures may not be needed routinely in patients with gram- negative bacteremia, it would be difficult to extrapolate this to gram-positive organisms, especially Staphylococcus aureus.

In Canzoneri et al,3 43 (78%) of the 55 positive follow-up cultures were due to gram-positive organisms. Factors associated with positive follow-up cultures were concurrent fever, presence of a central intravenous line, end-stage renal disease on hemodialysis, and diabetes mellitus. In addition, infectious disease consultation to decide the need for follow-up cultures for S aureus bacteremia has been associated with fewer deaths, fewer relapses, and lower readmission rates.6,7

In certain clinical scenarios, follow-up blood cultures can provide useful information, such as when the source of bacteremia is endocarditis or cardiac device infection, a vascular graft, or an intravascular line. In the Infectious Diseases Society of America guidelines for diagnosis and management of catheter-related bloodstream infections, persistent or relapsing bacteremia for some organisms is a criterion for removal of a long-term central venous catheter.8

Follow-up cultures are especially useful when the focus of infection is protected from antibiotic penetration, such as in the central nervous system, joints, and abdominal or other abscess. These foci may require drainage for cure. In these cases or in the setting of unfavorable clinical treatment response, follow-up blood cultures showing persistent bacteremia can prompt a search for unaddressed or incompletely addressed foci of infection and allow for source control.

The timing of follow-up cultures is generally 1 to 2 days after the initial culture. Although Mushtaq et al propose a different approach, traditional teaching has been that the last blood culture should not be positive, and this leads to ordering follow-up blood cultures until clearance of bacteremia is documented.

References
  1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013; 19(6):501–509. doi:10.1111/1469-0691.12195
  2. Mushtaq A, Bredell B, Soubani A. Repeating blood cultures after an initial bacteremia: when and how often? Cleve Clin J Med 2019; 86(2):89–92. doi:10.3949/ccjm.86a.18001
  3. Canzoneri CN, Akhavan BJ, Tosur Z, Andrade PEA, Aisenberg GM. Follow-up blood cultures in gram-negative bacteremia: are they needed? Clin Infect Dis 2017; 65(11):1776–1779. doi:10.1093/cid/cix648
  4. Jones RB, Paruchuri A, Shah SS. Prospective trials are required to alter practice for follow-up blood cultures for gram-negative bacilli bacteremia. Clin Infect Dis 2018; 67(2):315–316. doi:10.1093/cid/ciy070
  5. Kang CK, Kim ES, Song KH, et al. Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case-control study. BMC Infect Dis 2013; 13:365. doi:10.1186/1471-2334-13-365
  6. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123(7):631–637. doi:10.1016/j.amjmed.2010.01.015
  7. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27(3):478–486. pmid:9770144
  8. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1):1–45. doi:10.1086/599376
Article PDF
Author and Disclosure Information

Marisa Tungsiripat, MD
Head, Section of HIV, Department of Infectious Disease, Cleveland Clinic

Address: Marisa Tungsiripat, MD, Department of Infectious Disease, G21, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; tungsim@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 86(2)
Publications
Topics
Page Number
93-94
Legacy Keywords
bacteremia, blood cultures, hospital medicine, testing, Staphylococcus aureus, endovascular infection, endocarditis, gram-negative, Klebsiella pneumoniae, Marisa Tungsiripat
Sections
Author and Disclosure Information

Marisa Tungsiripat, MD
Head, Section of HIV, Department of Infectious Disease, Cleveland Clinic

Address: Marisa Tungsiripat, MD, Department of Infectious Disease, G21, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; tungsim@ccf.org

Author and Disclosure Information

Marisa Tungsiripat, MD
Head, Section of HIV, Department of Infectious Disease, Cleveland Clinic

Address: Marisa Tungsiripat, MD, Department of Infectious Disease, G21, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; tungsim@ccf.org

Article PDF
Article PDF
Related Articles

Bacteremia is common and associated with significant morbidity and mortality. Bloodstream infections rank among the leading causes of death in North America and Europe.1

See related article

In this issue, Mushtaq et al2 contend that follow-up blood cultures after initial bacteremia are not needed for most hospitalized patients. Not repeating blood cultures after initial bacteremia has been proposed to decrease hospitalization length, consultations, and healthcare costs in some clinical settings. However, without follow-up cultures, it can be difficult to assess the adequacy of treatment of bacteremia and associated underlying infections.

GRAM-NEGATIVE ORGANISMS

Results of retrospective studies indicate that follow-up cultures may not be routinely needed for gram-negative bacteremia. In a review by Canzoneri et al of 383 cases with subsequent follow-up cultures,3 55 (14%) were positive. The mean duration of bacteremia was 2.8 days (range 1 to 15 days). Of the 55 persistently positive blood cultures, only 8 (15%) were caused by gram-negative organisms. Limitations to this study included the lack of patient outcome data, a low event rate, and the retrospective design.4

In a retrospective case-control study of follow-up cultures for 862 episodes of Klebsiella pneumoniae bacteremia,5 independent risk factors for persistent bacteremia were intra-abdominal infection, higher Charlson comorbidity index score, solid-organ transplant, and unfavorable treatment response.

These studies confirm that persistent bacteremia is uncommon with gram-negative organisms. They also support using comorbidities and treatment response to guide the ordering of follow-up blood cultures.

WHEN IS FOLLOW-UP CULTURE USEFUL?

Although follow-up blood cultures may not be needed routinely in patients with gram- negative bacteremia, it would be difficult to extrapolate this to gram-positive organisms, especially Staphylococcus aureus.

In Canzoneri et al,3 43 (78%) of the 55 positive follow-up cultures were due to gram-positive organisms. Factors associated with positive follow-up cultures were concurrent fever, presence of a central intravenous line, end-stage renal disease on hemodialysis, and diabetes mellitus. In addition, infectious disease consultation to decide the need for follow-up cultures for S aureus bacteremia has been associated with fewer deaths, fewer relapses, and lower readmission rates.6,7

In certain clinical scenarios, follow-up blood cultures can provide useful information, such as when the source of bacteremia is endocarditis or cardiac device infection, a vascular graft, or an intravascular line. In the Infectious Diseases Society of America guidelines for diagnosis and management of catheter-related bloodstream infections, persistent or relapsing bacteremia for some organisms is a criterion for removal of a long-term central venous catheter.8

Follow-up cultures are especially useful when the focus of infection is protected from antibiotic penetration, such as in the central nervous system, joints, and abdominal or other abscess. These foci may require drainage for cure. In these cases or in the setting of unfavorable clinical treatment response, follow-up blood cultures showing persistent bacteremia can prompt a search for unaddressed or incompletely addressed foci of infection and allow for source control.

The timing of follow-up cultures is generally 1 to 2 days after the initial culture. Although Mushtaq et al propose a different approach, traditional teaching has been that the last blood culture should not be positive, and this leads to ordering follow-up blood cultures until clearance of bacteremia is documented.

Bacteremia is common and associated with significant morbidity and mortality. Bloodstream infections rank among the leading causes of death in North America and Europe.1

See related article

In this issue, Mushtaq et al2 contend that follow-up blood cultures after initial bacteremia are not needed for most hospitalized patients. Not repeating blood cultures after initial bacteremia has been proposed to decrease hospitalization length, consultations, and healthcare costs in some clinical settings. However, without follow-up cultures, it can be difficult to assess the adequacy of treatment of bacteremia and associated underlying infections.

GRAM-NEGATIVE ORGANISMS

Results of retrospective studies indicate that follow-up cultures may not be routinely needed for gram-negative bacteremia. In a review by Canzoneri et al of 383 cases with subsequent follow-up cultures,3 55 (14%) were positive. The mean duration of bacteremia was 2.8 days (range 1 to 15 days). Of the 55 persistently positive blood cultures, only 8 (15%) were caused by gram-negative organisms. Limitations to this study included the lack of patient outcome data, a low event rate, and the retrospective design.4

In a retrospective case-control study of follow-up cultures for 862 episodes of Klebsiella pneumoniae bacteremia,5 independent risk factors for persistent bacteremia were intra-abdominal infection, higher Charlson comorbidity index score, solid-organ transplant, and unfavorable treatment response.

These studies confirm that persistent bacteremia is uncommon with gram-negative organisms. They also support using comorbidities and treatment response to guide the ordering of follow-up blood cultures.

WHEN IS FOLLOW-UP CULTURE USEFUL?

Although follow-up blood cultures may not be needed routinely in patients with gram- negative bacteremia, it would be difficult to extrapolate this to gram-positive organisms, especially Staphylococcus aureus.

In Canzoneri et al,3 43 (78%) of the 55 positive follow-up cultures were due to gram-positive organisms. Factors associated with positive follow-up cultures were concurrent fever, presence of a central intravenous line, end-stage renal disease on hemodialysis, and diabetes mellitus. In addition, infectious disease consultation to decide the need for follow-up cultures for S aureus bacteremia has been associated with fewer deaths, fewer relapses, and lower readmission rates.6,7

In certain clinical scenarios, follow-up blood cultures can provide useful information, such as when the source of bacteremia is endocarditis or cardiac device infection, a vascular graft, or an intravascular line. In the Infectious Diseases Society of America guidelines for diagnosis and management of catheter-related bloodstream infections, persistent or relapsing bacteremia for some organisms is a criterion for removal of a long-term central venous catheter.8

Follow-up cultures are especially useful when the focus of infection is protected from antibiotic penetration, such as in the central nervous system, joints, and abdominal or other abscess. These foci may require drainage for cure. In these cases or in the setting of unfavorable clinical treatment response, follow-up blood cultures showing persistent bacteremia can prompt a search for unaddressed or incompletely addressed foci of infection and allow for source control.

The timing of follow-up cultures is generally 1 to 2 days after the initial culture. Although Mushtaq et al propose a different approach, traditional teaching has been that the last blood culture should not be positive, and this leads to ordering follow-up blood cultures until clearance of bacteremia is documented.

References
  1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013; 19(6):501–509. doi:10.1111/1469-0691.12195
  2. Mushtaq A, Bredell B, Soubani A. Repeating blood cultures after an initial bacteremia: when and how often? Cleve Clin J Med 2019; 86(2):89–92. doi:10.3949/ccjm.86a.18001
  3. Canzoneri CN, Akhavan BJ, Tosur Z, Andrade PEA, Aisenberg GM. Follow-up blood cultures in gram-negative bacteremia: are they needed? Clin Infect Dis 2017; 65(11):1776–1779. doi:10.1093/cid/cix648
  4. Jones RB, Paruchuri A, Shah SS. Prospective trials are required to alter practice for follow-up blood cultures for gram-negative bacilli bacteremia. Clin Infect Dis 2018; 67(2):315–316. doi:10.1093/cid/ciy070
  5. Kang CK, Kim ES, Song KH, et al. Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case-control study. BMC Infect Dis 2013; 13:365. doi:10.1186/1471-2334-13-365
  6. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123(7):631–637. doi:10.1016/j.amjmed.2010.01.015
  7. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27(3):478–486. pmid:9770144
  8. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1):1–45. doi:10.1086/599376
References
  1. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013; 19(6):501–509. doi:10.1111/1469-0691.12195
  2. Mushtaq A, Bredell B, Soubani A. Repeating blood cultures after an initial bacteremia: when and how often? Cleve Clin J Med 2019; 86(2):89–92. doi:10.3949/ccjm.86a.18001
  3. Canzoneri CN, Akhavan BJ, Tosur Z, Andrade PEA, Aisenberg GM. Follow-up blood cultures in gram-negative bacteremia: are they needed? Clin Infect Dis 2017; 65(11):1776–1779. doi:10.1093/cid/cix648
  4. Jones RB, Paruchuri A, Shah SS. Prospective trials are required to alter practice for follow-up blood cultures for gram-negative bacilli bacteremia. Clin Infect Dis 2018; 67(2):315–316. doi:10.1093/cid/ciy070
  5. Kang CK, Kim ES, Song KH, et al. Can a routine follow-up blood culture be justified in Klebsiella pneumoniae bacteremia? A retrospective case-control study. BMC Infect Dis 2013; 13:365. doi:10.1186/1471-2334-13-365
  6. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK. The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010; 123(7):631–637. doi:10.1016/j.amjmed.2010.01.015
  7. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27(3):478–486. pmid:9770144
  8. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1):1–45. doi:10.1086/599376
Issue
Cleveland Clinic Journal of Medicine - 86(2)
Issue
Cleveland Clinic Journal of Medicine - 86(2)
Page Number
93-94
Page Number
93-94
Publications
Publications
Topics
Article Type
Display Headline
Follow-up blood cultures are often needed after bacteremia
Display Headline
Follow-up blood cultures are often needed after bacteremia
Legacy Keywords
bacteremia, blood cultures, hospital medicine, testing, Staphylococcus aureus, endovascular infection, endocarditis, gram-negative, Klebsiella pneumoniae, Marisa Tungsiripat
Legacy Keywords
bacteremia, blood cultures, hospital medicine, testing, Staphylococcus aureus, endovascular infection, endocarditis, gram-negative, Klebsiella pneumoniae, Marisa Tungsiripat
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 01/28/2019 - 13:00
Un-Gate On Date
Mon, 01/28/2019 - 13:00
Use ProPublica
CFC Schedule Remove Status
Mon, 01/28/2019 - 13:00
Article PDF Media

Dyslipidemia in HIV patients

Article Type
Changed
Wed, 09/12/2018 - 11:05
Display Headline
Dyslipidemia in HIV patients
Article PDF
Author and Disclosure Information

Marisa Tungsiripat, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Judith A. Aberg, MD
Associate Professor of Medicine, Director of HIV, Bellevue Hospital Center, Director of AIDS Clinical Trials Unit, New York University

Address: Marisa Tungsiripat, MD, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; tungsim@ccf.org

Dr. Aberg has indicated that she is a consultant for Bristol-Myers Squibb, Boehringer-Ingelheim, Gilead Sciences, and Glaxo-SmithKline. She received research support from Bristol-Myers Squibb, Abbott, and Merck and is active in the leadership for the National Institute of Allergy and Infectious Diseases-sponsored AIDS Clinical Trials Group.

Issue
Cleveland Clinic Journal of Medicine - 72(12)
Publications
Topics
Page Number
1113-1120
Sections
Author and Disclosure Information

Marisa Tungsiripat, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Judith A. Aberg, MD
Associate Professor of Medicine, Director of HIV, Bellevue Hospital Center, Director of AIDS Clinical Trials Unit, New York University

Address: Marisa Tungsiripat, MD, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; tungsim@ccf.org

Dr. Aberg has indicated that she is a consultant for Bristol-Myers Squibb, Boehringer-Ingelheim, Gilead Sciences, and Glaxo-SmithKline. She received research support from Bristol-Myers Squibb, Abbott, and Merck and is active in the leadership for the National Institute of Allergy and Infectious Diseases-sponsored AIDS Clinical Trials Group.

Author and Disclosure Information

Marisa Tungsiripat, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation

Judith A. Aberg, MD
Associate Professor of Medicine, Director of HIV, Bellevue Hospital Center, Director of AIDS Clinical Trials Unit, New York University

Address: Marisa Tungsiripat, MD, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; tungsim@ccf.org

Dr. Aberg has indicated that she is a consultant for Bristol-Myers Squibb, Boehringer-Ingelheim, Gilead Sciences, and Glaxo-SmithKline. She received research support from Bristol-Myers Squibb, Abbott, and Merck and is active in the leadership for the National Institute of Allergy and Infectious Diseases-sponsored AIDS Clinical Trials Group.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 72(12)
Issue
Cleveland Clinic Journal of Medicine - 72(12)
Page Number
1113-1120
Page Number
1113-1120
Publications
Publications
Topics
Article Type
Display Headline
Dyslipidemia in HIV patients
Display Headline
Dyslipidemia in HIV patients
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media